SCHEMBL16210907

SCHEMBL16210907

CC(C)(N)C1CCC(Nc2ccc3ncc(-c4cccc(Cl)c4)n3n2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 20/20 1.00
KCNH2 Q12809 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14653632 1.00 PIM1 (1.00) PIM1KCNH2
SCHEMBL20794108 1.00 PIM1 (1.00) PIM1KCNH2
SCHEMBL19986935 0.92 PIM1 (1.00) PIM1KCNH2
SCHEMBL102411 0.92 PIM1 (1.00) PIM1KCNH2
SCHEMBL14653638 0.89 PIM1 (1.00) PIM1KCNH2
SCHEMBL16210904 0.89 PIM1 (1.00) PIM1KCNH2
SCHEMBL19986984 0.89 PIM1 (1.00) PIM1KCNH2
SCHEMBL16211051 0.89 PIM1 (1.00) PIM1KCNH2
SCHEMBL14653584 0.89 PIM1 (1.00) PIM1KCNH2
SCHEMBL14653626 0.89 PIM1 (1.00) PIM1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320217-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA INC (US) 2025-10-16 US disclosed
US-20250129085-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA INC (US) 2025-04-24 US disclosed
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2021-08-05 US disclosed
EP-3812387-A1 HETEROCYCLIC PROTEIN KINASE INHIBITORS Sumitomo Dainippon Pharma Oncology, Inc. (US) 2021-04-28 EP disclosed
US-10875864-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2020-12-29 US disclosed
EP-3409278-B1 HETEROCYCLIC PROTEIN KINASE INHIBITORS TOLERO PHARMACEUTICALS INC (US) 2020-09-16 EP disclosed
US-20200102313-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2020-04-02 US disclosed
US-10392392-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2019-08-27 US disclosed
US-20190071446-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2019-03-07 US disclosed
EP-3409278-A1 HETEROCYCLIC PROTEIN KINASE INHIBITORS Tolero Pharmaceuticals, Inc. (US) 2018-12-05 EP disclosed
EP-2734205-B1 HETEROCYCLIC PROTEIN KINASE INHIBITORS TOLERO PHARMACEUTICALS INC (US) 2018-03-21 EP disclosed
US-20170002014-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS SUMITOMO PHARMA AMERICA, INC. 2017-01-05 US disclosed
US-9416132-B2 Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors TOLERO PHARMACEUTICALS, INC. (US) 2016-08-16 US disclosed
US-20140329807-A1 HETEROCYCLIC PROTEIN KINASE INHIBITORS TOLERO PHARMACEUTICALS, INC. (US) 2014-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875864-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors PIM2, PIM1, PIM3 PIM1 2/4885KCNH2 1630/4885
US-20190071446-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1832/4885
US-20210238183-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1832/4885
US-20250129085-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1832/4885
US-20200102313-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1832/4885
US-20140329807-A1 HETEROCYCLIC PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1599/4885
US-10392392-B2 Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1584/4885
US-20250320217-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1832/4885
US-20170002014-A1 SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885KCNH2 1832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.